Intravenous iron preparations have been shown to be superior to oral iron and have largely replaced the treatment of anemia in Northern countries. However, the socioeconomic and medical conditions in low resource countries greatly differ from those in northern countries. Patients’ different access to medication supply, perception of medication need and compliance as well as the burden of concomitant disease like malaria, soil-transmitted helminths, schistosomiasis, HIV and red blood cells (RBC) genetic disorders may influence effectiveness and safety of iron substitution modality.
The aim of the study is to compare iv iron substitution by ferric carboxymaltose (Ferinject®) to per oral iron substitution in a low resource country.